3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Prostatic Neoplasms
33
Neoplasms
3
Breast Neoplasms
3
Triple Negative Breast Neoplasms
2
Prostatic Neoplasms, Castration-Resistant
2
mCRPC
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Salivary Cancer
1
Recurrence
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Metastatic Hormone-sensitive Prostate Cancer
1
Metastatic Hormone Sensitive Prostate Cancer
1
Metastatic Castration-resistant Prostate Cancer
1
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
1
Melanoma
1
Liposarcoma
1
Lethal Congenital Contracture Syndrome 2
1
Fibromatosis, Gingival, 2
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Dementia
1
Colorectal Neoplasms
1
Cognitive Dysfunction
1
Castration-resistant Prostate Cancer Patients with Oligometastases
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Carboplatin
3
Taxes
2
Radiotherapy
2
Radiosurgery
2
Radiation
2
Paclitaxel
2
Nivolumab
2
veliparib
1
tislelizumab
1
spartalizumab
1
sotorasib
1
pembrolizumab
1
pegylated granulocyte colony-stimulating factor
1
pegfilgrastim
1
enzalutamide
1
apatinib
1
Radiotherapy, Image-Guided
1
Radiotherapy, Conformal
1
Platinum
1
Pemetrexed
1
Morphine
1
Midazolam
1
Letrozole
1
Ipilimumab
1
Immunoglobulin G
1
Granulocyte Colony-Stimulating Factor
1
Geriatric Assessment
1
Fulvestrant
1
Filgrastim
1
Etoposide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Adenocarcinoma of Lung
×
enzalutamide
×
Clear all
NCT04557449
2025-10-01
CDK4i
Pfizer
Phase 2
Active not recruiting
362 enrolled